About the company

JSC DALHIMPHARM is a modern complex of a full production cycle: from active pharmaceutical substances to finished medicines

In 2024, DALHIMPHARM turned 85 years old. Founded in February 1939, the company is currently the flagship of the pharmaceutical industry in the Far Eastern Federal District. During this long period of time, its formation took place: scientific and practical experience was gained, human resources were formed, production technology and equipment were improved. For many years, the company has been one of the top 30 Russian pharmaceutical manufacturing companies.

IMPORT SUBSTITUTION AND ECONOMICS

Over the past decade (2013-2023), the pharmaceutical industry has become one of the most developing sectors of the domestic industry. It was during this period that there was a steady increase in the production of original domestic drugs on the domestic market, and independence from foreign suppliers was significantly strengthened.

The positive growth dynamics of DALHIMPHARM can be clearly seen during this period. Thus, in 2013, the volume of production of medicines in value terms amounted to 1.4 billion rubles. And by the end of 2023 — 3.2 billion rubles. Thus, the increase in production increased by more than 2 times. The production of medicinal products within the framework of the import substitution strategy and increasing the availability of medicines is constantly increasing. Currently, medicines are being manufactured in almost all key segments of the pharmaceutical market. Along with antipyretic, antispasmodic, hemostatic, antimicrobial, analgesic, psychotropic drugs, the company produces ophthalmic drugs, medicines for the treatment of cardiovascular diseases, antipsychotics, etc. The company's product portfolio includes more than 200 drugs in various dosages and dosage forms, of which 70% are included in the list of vital and essential medicines. The volume of manufactured products is constantly growing: on an annual basis, production reached 40 million packs of injectable solutions, 800 million tablets, 6 million packs of suppositories and 5 million bottles of infusion solutions.

INVESTMEN

One of the priority areas of DALHIMPHARM's activities is currently the implementation of import substitution projects to localize the full production cycle of antieleptic and anxiolytic drugs in Russia, as well as medicines for the treatment of orphan (rare) diseases, etc. A site for the production of active pharmaceutical substances has been created on the existing production facilities. In addition, the company is actively investing in the construction, reconstruction and technical re-equipment of production. Over the five-year period, the volume of capital investments amounted to more than 500 million rubles. In 2023, the company commissioned a new production complex with a total area of over 2,100 m2. Thanks to the new complex, it was possible to increase the volume of production of new-generation antitumor drugs and antibiotics. JSC DALHIMPHARM is an enterprise of high production culture. The quality system is maintained throughout the entire product lifecycle: from the stage of drug development to the stage of their sale to the end user. DALHIMPHARM does not stand still in the field of registration and technology transfer of medicines. Every year, the product line is supplemented with at least five names of innovative medicines. The company is engaged in pharmaceutical development and conducts independent research to improve the properties of manufactured medicines and register original medicines that have no analogues, including in Russia.

The company has established and successfully implemented a pharmaceutical quality system. All production sites comply with international standards of good manufacturing practice (GMP), and the logistics system operates according to the requirements of good distribution practice (GDP). In addition, suffice it to say that out of 1,000 employees, more than 100 at the enterprise are specialists responsible for ensuring quality control. The existing environmental standards at the enterprise allow us to speak with confidence about environmentally friendly pharmaceutical production.

COMPETENCIES

An important link in DALHIMPHARM's investment policy is financial investments in personnel training and increasing the intellectual potential of the organization. It is highly qualified specialists who determine its present and future. The company has a staff training and development policy. The company considers it necessary to maintain the professional qualifications of specialists by organizing regular training for each of them in external organizations or within the framework of the organization's personnel training system. The innovative future of the domestic pharmaceutical industry begins today, so we understand how important it is not to miss the chance and start acting now. DALHIMPHARM has developed and successfully implemented a project to work with leading specialized educational institutions in the Far East and Siberia. Every year, students from various educational institutions undergo practical training in factory workshops and laboratories. Staff training is the main priority when forming company development plans. DALHIMPHARM is a participant in the program "Increasing labor mobility", according to which residents of the Russian Federation can move to permanent residence in the Khabarovsk Territory and receive financial support, including: a one-time payment in the amount of.

A LOOK INTO THE FUTURE

Throughout its 85—year history, the company, which began its journey on the eve of the Great Patriotic War as a strategic facility, almost immediately launched the production of various forms of medicines, from dressings and first-aid kits to complex multicomponent drugs with a wide range of effects. The company's team has accumulated extensive experience, starting with the development and synthesis of substances, ending with the production of finished medicines. The company is dynamically developing, implementing a number of conceptual investment projects and occupies a strong position in the pharmaceutical market not only in Russia, but also in such countries as Azerbaijan, Tajikistan, Kazakhstan, Uzbekistan, Mongolia, etc. The company's vital products that meet international standards are recognizable, in demand and accessible to all segments of the population. Focusing on the consumer and using their unique knowledge and long-term experience, the team of JSC DALHIMPHARM will continue to expand the portfolio of available medicines, offering reasonable solutions that raise the level of modern drug therapy.

A TEST OF STRENGTH

During the difficult epidemiological situation in the country, DALHIMPHARM made a significant contribution to solving the issue of increasing the production of medicines included by the Russian Ministry of Health in the recommendations for treatment of coronavirus infection COVID‑19. Despite the limited production capacity, the company quickly launched an increased production of antibiotics (levofloxacin, amoxicillin) and glucocorticosteroids (dexamethasone) for domestic needs. In addition, the company actively participated in emergency supplies of medicines to reduce the current acute defect in the national pharmaceutical markets of Kazakhstan and Uzbekistan.